CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.11 | -0.05 | 0.08 |
| FCF Yield | -67.87% | -23.22% | -109.30% | -38.89% |
| EV / EBITDA | -1.49 | -4.63 | 0.89 | -2.23 |
| Quality | ||||
| ROIC | -111.54% | -41.67% | -34.41% | -32.35% |
| Gross Margin | 39.06% | 59.19% | 63.28% | 58.38% |
| Cash Conversion Ratio | 0.74 | 0.74 | 0.52 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.85% | 3.94% | 41.73% | 94.01% |
| Free Cash Flow Growth | -32.67% | 16.82% | 36.94% | 6.35% |
| Safety | ||||
| Net Debt / EBITDA | -0.25 | -0.19 | 1.90 | 1.03 |
| Interest Coverage | -45.49 | 0.00 | -427.27 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.31 | 0.87 | 2.58 | 6.58 |
| Cash Conversion Cycle | 249.35 | 411.19 | 175.55 | 34.83 |